AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34133089 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7269
Study 32962749 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi/Qigong (TCQ) intervention
Number of subjects: 72
Study 32962749 — intervention group
Group type: COMPARATOR
Intervention: Sham qigong control
Number of subjects: 72
Study 32962749 — intervention group
Group type: COMPARATOR
Intervention: Standard of care control
Number of subjects: 72
Study 35792053 — intervention group
Group type: EXPERIMENTAL
Intervention: Approach Bias Modification (ApBM)
Number of subjects: 300
Study 32936480 — intervention group
Group type: EXPERIMENTAL
Intervention: Tisseel plus PEP (TEPEP) patch
Number of subjects: 3
Study 32936480 — intervention group
Group type: EXPERIMENTAL
Intervention: Tisseel patch alone
Number of subjects: 3
Study 32936480 — intervention group
Group type: COMPARATOR
Intervention: Control (FDP tendon repair alone)
Number of subjects: 3
Study 32211049 — intervention group
Group type: COMPARATOR
Intervention: Food-secure households
Number of subjects: 525
Study 32211049 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately food-insecure households
Number of subjects: 525
Study 32211049 — intervention group
Group type: EXPERIMENTAL
Intervention: Food-insecure households
Number of subjects: 525
Study 32211049 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall child undernutrition
Number of subjects: 525
Study 32211049 — intervention group
Group type: EXPERIMENTAL
Intervention: Household food insecurity
Number of subjects: 525
Study 35083238 — intervention group
Group type: EXPERIMENTAL
Intervention: Faecal microbiota transplantation (FMT)
Number of subjects: 60
Study 35879196 — intervention group
Group type: EXPERIMENTAL
Intervention: 5000 IU HCG
Number of subjects: 94
Study 35879196 — intervention group
Group type: EXPERIMENTAL
Intervention: 6500 IU HCG
Number of subjects: 94
Study 35879196 — intervention group
Group type: EXPERIMENTAL
Intervention: 10,000 IU HCG
Number of subjects: 94
Study 35879196 — intervention group
Group type: COMPARATOR
Intervention: 6500 IU HCG with vaginal progesterone
Number of subjects: 94
Study 35879196 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between groups
Number of subjects: 94
Study 34499672 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (2000 mg/day)
Number of subjects: 117
Study 34499672 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 34499672 — intervention group
Group type: EXPERIMENTAL
Intervention: PCOS status (mothers)
Number of subjects: 117
Study 34499672 — intervention group
Group type: COMPARATOR
Intervention: Reference population
Number of subjects: 117
Study 36045119 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg oral hydrocortisone
Number of subjects: 120
Study 36045119 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 120
Study 33713817 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG IFN‐α2b plus SOC
Number of subjects: 40
Study 33713817 — intervention group
Group type: COMPARATOR
Intervention: SOC
Number of subjects: 40
Study 35150597 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth-containing quadruple therapy (BQT)
Number of subjects: 292
Study 35150597 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole plus amoxicillin dual therapy (RADT)
Number of subjects: 292
Study 35150597 — intervention group
Group type: EXPERIMENTAL
Intervention: Furazolidone (RFDT)
Number of subjects: 292
Study 33283636 — intervention group
Group type: EXPERIMENTAL
Intervention: Management of local intravascular coagulopathy (LIC) with low‐molecular‐weight heparin (LMWH) and other anticoagulants
Number of subjects: 0
Study 33283636 — intervention group
Group type: EXPERIMENTAL
Intervention: Various treatment options including compression, sclerotherapy, laser therapy, cryoablation, and surgery
Number of subjects: 0
Study 33283636 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted molecular therapies acting on the PI3Kinase/AKT/mTOR pathway
Number of subjects: 0
Study 33283636 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized risk stratification tools and quality of life (QOL) questionnaires
Number of subjects: 0
Study 35749373 — intervention group
Group type: EXPERIMENTAL
Intervention: Warning Label (WL)
Number of subjects: 14880
Study 35749373 — intervention group
Group type: COMPARATOR
Intervention: Guideline Daily Amount (GDA)
Number of subjects: 14880
Study 34336630 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 µ/kg dexmedetomidine with 20 mL bupivacaine 0.125% (Group L)
Number of subjects: 80
Study 34336630 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 µ/kg dexmedetomidine with 20 mL bupivacaine 0.125% (Group M)
Number of subjects: 80
Study 34336630 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 µ/kg dexmedetomidine with 20 mL bupivacaine 0.125% (Group H)
Number of subjects: 80
Study 34039876 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) for 16 weeks followed by a 12-week maintenance phase with mobile health coaching.
Number of subjects: 100
Study 34039876 — intervention group
Group type: COMPARATOR
Intervention: Continuous Moderate Exercise (CME) for 16 weeks followed by a 12-week maintenance phase with mobile health coaching.
Number of subjects: 100
Study 34600297 — intervention group
Group type: EXPERIMENTAL
Intervention: Go trials (50% probability)
Number of subjects: 0
Study 34600297 — intervention group
Group type: COMPARATOR
Intervention: Cued condition (80% Go probability)
Number of subjects: 0
Study 34816311 — intervention group
Group type: EXPERIMENTAL
Intervention: Reverse‐TAP
Number of subjects: 52
Study 34816311 — intervention group
Group type: COMPARATOR
Intervention: DK‐crush
Number of subjects: 52
Study 33481401 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitric oxide
Number of subjects: 110
Study 33481401 — intervention group
Group type: EXPERIMENTAL
Intervention: fHb ratio
Number of subjects: 110
Study 33420349 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype-guided pain management
Number of subjects: 260
Study 33420349 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 260
Study 33715871 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulipristal acetate (UPA) 10 mg orally once a day for 12 weeks
Number of subjects: 161
Study 33715871 — intervention group
Group type: COMPARATOR
Intervention: Leuprorelin acetate (LEU) 1.88 mg or 3.75 mg subcutaneously at weeks 0, 4, and 8
Number of subjects: 161
Study 33715871 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulipristal acetate (UPA)
Number of subjects: 161
Study 33715871 — intervention group
Group type: COMPARATOR
Intervention: Leuprorelin acetate (LEU)
Number of subjects: 161
Study 35801957 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 330
Study 32920492 — intervention group
Group type: EXPERIMENTAL
Intervention: Blonanserin (BNS)
Number of subjects: 61
Study 32920492 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (OLZ)
Number of subjects: 61
Study 32920492 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 61
Study 33764158 — intervention group
Group type: EXPERIMENTAL
Intervention: IMACS Risk Score
Number of subjects: 15187
Study 33764158 — intervention group
Group type: COMPARATOR
Intervention: Heartmate II Risk Score
Number of subjects: 15187
Study 33186365 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTION Respecting Choices ACP intervention
Number of subjects: 1117
Study 33186365 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (Control)
Number of subjects: 1117
Study 35477635 — intervention group
Group type: EXPERIMENTAL
Intervention: REL-1017 25 mg (75 mg loading dose on day 1)
Number of subjects: 62
Study 35477635 — intervention group
Group type: EXPERIMENTAL
Intervention: REL-1017 50 mg (100 mg loading dose on day 1)
Number of subjects: 62
Study 35477635 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 34865562 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress group (experienced stressors including smoke, fire, and explosions)
Number of subjects: 40
Study 34865562 — intervention group
Group type: COMPARATOR
Intervention: Control group (no stressors)
Number of subjects: 40
Study 34865562 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress group
Number of subjects: 40
Study 36438822 — intervention group
Group type: EXPERIMENTAL
Intervention: Kampo group receiving mixed extract granules of kakkonto (2.5 g) and shosaikotokakikyosekko (2.5 g) three times a day for 14 days in addition to conventional treatment
Number of subjects: 161
Study 36438822 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving conventional treatment for symptom relief such as antipyretics and antitussives
Number of subjects: 161
Study 36438822 — intervention group
Group type: EXPERIMENTAL
Intervention: Kampo group
Number of subjects: 161
Study 35999689 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiring Virtual Enabled Resources following Vascular Events (iVERVE) - electronic messages aligned to personal goals, 4-week duration.
Number of subjects: 54
Study 35999689 — intervention group
Group type: COMPARATOR
Intervention: Control group - limited administrative messages.
Number of subjects: 54
Study 33545619 — intervention group
Group type: EXPERIMENTAL
Intervention: Italian version of the Body Appreciation Scale-2 (BAS-2)
Number of subjects: 601
Study 36423400 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise&Education
Number of subjects: 163
Study 36423400 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 163
Study 36423400 — intervention group
Group type: COMPARATOR
Intervention: Control (CPC)
Number of subjects: 163
Study 34127092 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumateperone 42mg
Number of subjects: 256
Study 34127092 — intervention group
Group type: COMPARATOR
Intervention: Risperidone 4mg
Number of subjects: 256
Study 32013530 — intervention group
Group type: EXPERIMENTAL
Intervention: T'ai Chi (TC)
Number of subjects: 57
Study 32013530 — intervention group
Group type: COMPARATOR
Intervention: Health Education (HE)
Number of subjects: 57
Study 32013530 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 57
Study 35617296 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic malaria parasitaemia
Number of subjects: 1587
Study 35617296 — intervention group
Group type: EXPERIMENTAL
Intervention: Not sleeping under a bednet
Number of subjects: 1587
Study 35617296 — intervention group
Group type: EXPERIMENTAL
Intervention: Illiterate parent or guardian
Number of subjects: 1587
Study 35617296 — intervention group
Group type: EXPERIMENTAL
Intervention: History of malaria in the past one month
Number of subjects: 1587
Study 35617296 — intervention group
Group type: EXPERIMENTAL
Intervention: Stunted children
Number of subjects: 1587
Study 34127045 — intervention group
Group type: EXPERIMENTAL
Intervention: Ca-polyP graft material only
Number of subjects: 8
Study 34127045 — intervention group
Group type: EXPERIMENTAL
Intervention: Ca-polyP in combination with biphasic calcium phosphate (BCP)
Number of subjects: 8
Study 32677930 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-child communication about sexual issues (perceived comfort in communication)
Number of subjects: 4343
Study 32677930 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-child communication about sexual issues (parental connection)
Number of subjects: 4343
Study 32677930 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-child communication about sexual issues (fear-based communication)
Number of subjects: 4343
Study 32677930 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-child communication about sexual issues (opposition to contraception education)
Number of subjects: 4343
Study 32677930 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-child communication about sexual issues (school enrollment status)
Number of subjects: 4343
Study 34850164 — intervention group
Group type: EXPERIMENTAL
Intervention: eGo-style ENDS with 36 mg/ml nicotine liquid
Number of subjects: 520
Study 34850164 — intervention group
Group type: EXPERIMENTAL
Intervention: eGo-style ENDS with 0 mg/ml nicotine liquid
Number of subjects: 520
Study 34850164 — intervention group
Group type: EXPERIMENTAL
Intervention: eGo-style ENDS with 8 mg/ml nicotine liquid
Number of subjects: 520
Study 34850164 — intervention group
Group type: COMPARATOR
Intervention: Cigarette substitute (CS)
Number of subjects: 520
Study 35486921 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided axillary brachial plexus block
Number of subjects: 20
Study 35486921 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard analgesia)
Number of subjects: 20
Study 33345388 — intervention group
Group type: EXPERIMENTAL
Intervention: Premium hearing aids (A)
Number of subjects: 22
Study 33345388 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic hearing aids (B)
Number of subjects: 22
Study 33345388 — intervention group
Group type: COMPARATOR
Intervention: No amplification (C)
Number of subjects: 22
Study 34969263 — intervention group
Group type: EXPERIMENTAL
Intervention: One-Shot Dilatation (OSD) using a single Amplatz dilator (30F)
Number of subjects: 150
Study 34969263 — intervention group
Group type: COMPARATOR
Intervention: Metal Telescopic Dilator (MTD) using sequential MTD (9-30F)
Number of subjects: 150
Study 32193622 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 94
Study 32193622 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine
Number of subjects: 94
Study 36071530 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component intervention including Menstrual Health Action Group, NGO-led training, drama skit, menstrual health kit (reusable pads and menstrual cups), pain management strategies, and improvements to school facilities.
Number of subjects: 3600
Study 32323166 — intervention group
Group type: EXPERIMENTAL
Intervention: Getting To Outcomes (GTO) implementation support intervention
Number of subjects: 29
Study 32323166 — intervention group
Group type: COMPARATOR
Intervention: Control sites
Number of subjects: 29
Study 35470551 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphetamine (AMPH) 30 mg
Number of subjects: 10
Study 35470551 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 32456807 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 35937386 — intervention group
Group type: EXPERIMENTAL
Intervention: Microneedle injection of MEBO combined with blood transfusion
Number of subjects: 60
Study 35937386 — intervention group
Group type: EXPERIMENTAL
Intervention: Moist exposed burn ointment (MEBO) combined with blood transfusion
Number of subjects: 60
Study 35937386 — intervention group
Group type: COMPARATOR
Intervention: Calcipotriol ointment external application
Number of subjects: 60
Study 34167872 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin plus standard of care
Number of subjects: 124
Study 34167872 — intervention group
Group type: COMPARATOR
Intervention: Standard of care alone
Number of subjects: 124
Study 32119816 — intervention group
Group type: EXPERIMENTAL
Intervention: Sound enrichment procedures for 2 weeks
Number of subjects: 19
Study 32119816 — intervention group
Group type: COMPARATOR
Intervention: Control group (no sound enrichment)
Number of subjects: 19
Study 34256536 — intervention group
Group type: EXPERIMENTAL
Intervention: Core muscle strengthening exercise protocol for six weeks, 3 days a week.
Number of subjects: 98
Study 34256536 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise program, continued usual cricket training).
Number of subjects: 98
Study 34018333 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal vmPFC tDCS
Number of subjects: 16
Study 34018333 — intervention group
Group type: COMPARATOR
Intervention: Anodal r-TPJ tDCS
Number of subjects: 16
Study 34018333 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 16
Study 34110742 — intervention group
Group type: EXPERIMENTAL
Intervention: EMPWR intervention
Number of subjects: 301
Study 34110742 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 301
Study 34027853 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 47
Study 34027853 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 34793376 — intervention group
Group type: EXPERIMENTAL
Intervention: Every-other-day fasting
Number of subjects: 0
Study 34793376 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 35713267 — intervention group
Group type: EXPERIMENTAL
Intervention: IIP+CTG
Number of subjects: 30
Study 32788001 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiated teeth (exposed to radiation at a dose fraction of two Gy for five consecutive days until reaching a total dose of 60 Gy)
Number of subjects: 12
Study 32788001 — intervention group
Group type: COMPARATOR
Intervention: Nonirradiated teeth
Number of subjects: 12
Study 33745460 — intervention group
Group type: EXPERIMENTAL
Intervention: Legume-enriched diet (LD) group
Number of subjects: 400
Study 33745460 — intervention group
Group type: COMPARATOR
Intervention: Usual diet (UD) group
Number of subjects: 400
Study 35487422 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided subcostal TAP block (USTAP)
Number of subjects: 110
Study 35487422 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic subcostal TAP block (LSTAP)
Number of subjects: 110
Study 35487422 — intervention group
Group type: COMPARATOR
Intervention: Control group (no TAP block)
Number of subjects: 110
Study 35487422 — intervention group
Group type: EXPERIMENTAL
Intervention: USTAP and LSTAP
Number of subjects: 110
Study 35578213 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Working Approach intervention
Number of subjects: 200
Study 35578213 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 200
Study 34714252 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-directed digitally delivered intervention (web-based education, exercise, and physical activity program supported by automated exercise behavior change mobile phone text messages)
Number of subjects: 206
Study 34714252 — intervention group
Group type: COMPARATOR
Intervention: Control group (web-based education alone)
Number of subjects: 206
Study 34714252 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-directed digitally delivered intervention
Number of subjects: 206
Study 34714252 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 206
Study 33792451 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV) prescribed to patients with SVC decline; compliance recorded as used ≥2 h/24 h.
Number of subjects: 565
Study 33792451 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV) prescribed to patients with SVC decline; compliance recorded as used ≥4 h/24 h.
Number of subjects: 565
Study 33792451 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV) prescribed to patients with SVC decline; compliance recorded as used ≥22 h/24 h.
Number of subjects: 565
Study 33792451 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV) prescribed to patients with SVC decline; reasons for prescription.
Number of subjects: 565
Study 33792451 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV) prescribed to patients with SVC decline; follow-up of patients with SVC below 50%.
Number of subjects: 565
Study 33331406 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month follow-up interval (Group 1)
Number of subjects: 224
Study 33331406 — intervention group
Group type: COMPARATOR
Intervention: 18-month follow-up interval (Group 2)
Number of subjects: 224
Study 33331406 — intervention group
Group type: EXPERIMENTAL
Intervention: Both follow-up intervals
Number of subjects: 224
Study 33331406 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher number of teeth with initial active lesions
Number of subjects: 224
Study 33446872 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal ultrasound
Number of subjects: 130
Study 33446872 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI)
Number of subjects: 130
Study 32474710 — intervention group
Group type: EXPERIMENTAL
Intervention: Pudendal nerve block
Number of subjects: 49
Study 36350098 — intervention group
Group type: EXPERIMENTAL
Intervention: SuperPATH approach
Number of subjects: 101
Study 36350098 — intervention group
Group type: COMPARATOR
Intervention: Posterior approach
Number of subjects: 101
Study 35605013 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg daily oral tamoxifen
Number of subjects: 42
Study 35605013 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg daily oral tamoxifen
Number of subjects: 42
Study 35605013 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 42
Study 33403822 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-year multi-domain lifestyle intervention
Number of subjects: 1207
Study 33403822 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1207
Study 35343332 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast with compression (CwC) therapy
Number of subjects: 10
Study 35343332 — intervention group
Group type: COMPARATOR
Intervention: No therapy (control)
Number of subjects: 10
Study 32914483 — intervention group
Group type: EXPERIMENTAL
Intervention: Black barberry extract (1,000 mg, two capsules daily for 12 weeks)
Number of subjects: 80
Study 32914483 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin placebo (two capsules daily for 12 weeks)
Number of subjects: 80
Study 35730943 — intervention group
Group type: EXPERIMENTAL
Intervention: Portable HEPA filter air cleaners used from a median of 11 weeks gestation until the end of pregnancy
Number of subjects: 540
Study 35730943 — intervention group
Group type: COMPARATOR
Intervention: No air cleaners (control group)
Number of subjects: 540
Study 32394103 — intervention group
Group type: EXPERIMENTAL
Intervention: AI-guided PVI
Number of subjects: 226
Study 32394103 — intervention group
Group type: COMPARATOR
Intervention: CF-guided PVI
Number of subjects: 226
Study 35895150 — intervention group
Group type: EXPERIMENTAL
Intervention: Khanya intervention (cognitive-behavioral therapy-based)
Number of subjects: 61
Study 35895150 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Treatment as Usual (ETAU)
Number of subjects: 61
Study 33471853 — intervention group
Group type: EXPERIMENTAL
Intervention: Haematological parameters (RBC, Hb, HCT, MCV, PLT, WBC)
Number of subjects: 1227
Study 33471853 — intervention group
Group type: EXPERIMENTAL
Intervention: Biochemical analytes (Urea, Cr, Trig, HDL-C, AST, ALT, ALP, GGT, BID, BIT, Prot-T, Albumin)
Number of subjects: 1227